MESSAGE FROM FOUNDER
We live in an unprecedented time of innovation where technology advancements across numerous fields are converging. Furthermore, the multitude of tools that are available to us have never been more accessible. This is particularly true within the life sciences and medicine. Advanced fields are intersecting in a synergistic manner to accelerate cures.
The emergence of induced pluripotent stem cell (iPSC) technology is revolutionizing the drug discovery and regenerative medicine industries. With the ability to create patient and disease specific cell models, we can better understand human disease and predict human response. Human iPSC technology has captured my imagination from the very first reprogramming experiment and it has remained my passion and focus for research.
EverCell was founded to help accelerate the adoption of iPSC technology for commercial use. Human iPSC technology can offer numerous advantages but it is important to fully understand the limitations, as well as, the benefits. Given its continual and rapid evolution, iPSC technology will continue to be refined during its development. Having utilizing iPSCs since they were first discovered, EverCell was built to help navigate any challenges and facilitate the use iPSC technology.
Philip Manos is a stem cell expert with a successful history of technology development and business operations within both academic and commercial organizations. With more than a decade of pluripotent stem cell (iPSC) expertise, he has developed a strong publication record focused on human iPSC technology, including reprogramming via modified mRNA. Philip founded EverCell Bio in 2017 and currently serves as the President/CEO.
VISION, MISSION & VALUES
EVERCELL BIO FACILITATES AND ENHANCES THE APPLICATION OF PLURIPOTENT STEM CELL BASED RESEARCH BY PROVIDING THE MOST COMPREHENSIVE AND HIGHEST QUALITY OF CUSTOMIZED CELL MODELING AND PRODUCT SERVICES.
EverCell Bio aligns customer program needs with the most advanced stem cell technology and techniques in an effective process that yields deliverable results. With an advisory team comprising of over 30 years of combined pluripotent stem cell experience, EverCell Bio’s service platform combines industrial systems, research methodologies and proven strategies to meet a broad range of scientific needs in an efficient service package.
EverCell Bio exemplifies a holistic philosophy that focuses on customized solutions, customer care, effective communication and quality science. By fostering collaborative environments of high scientific quality, EverCell Bio catalyzes and facilitates the utilization of pluripotent stem cell technology and establishes a new standard for stem cell service.
Quality Integrity Efficient Collaborative Innovative
SCIENTIFIC ADVISORY BOARD
THORSTEN M. SCHLAEGER
Head of hESC Core Facility HSCI BOSTON CHILDREN’S HOSPITAL
Thorsten studied Human Biology at the University of Marburg and performed his Ph.D. thesis in the laboratories of Werner Risau and Tom Sato. In 1999 he was awarded the Otto Hahn Medal of Max Planck Society for his Ph.D. thesis. His postdoctoral research was performed in the laboratory of Stuart Orkin and then re-joined Boston Children’s Hospital after a brief time in industry. He currently works with Dr. Zon and Dr. Daley to develop hiPSC based transfusion and transplantation products. His laboratory focuses on human pluripotent stem cell biology, genome editing, reprogramming, laboratory automation, chemical genetics and imaging technologies.
Chief Scientific Officer
Brad is the Chief Scientific Officer for LifeVault Bio, Inc. Prior to joining LifeVault, Brad was the Chief Technology Officer for ReproCELL, Inc., and founding Scientist and Director of Research and Development for Stemgent, Inc. His 20 years experience in biotech focused on commercialization of translational technologies. He is a member of the International Society of Stem Cell Research (ISSCR), also serving on the Industry Committee.